1. Research Framework
1. Research Objective
2. Product Overview
2. Research Methodology
1. Qualitative Research
1. Primary and Secondary Sources
2. Quantitative Research
1. Primary and Secondary Sources
3. Breakdown of Primary Research Respondents, By Industry Participants

2.4.   Market Breakdown & Data Triangulation

2.5. Assumptions & Limitations

3. Executive Summary
4. U.S. PrEP Market – Industry Insights
1. Industry Value Chain Analysis
2. DROC Analysis
1. Growth Drivers
2. Restraints
3. Opportunity
4. Challenges
3. Recent Developments
4. Regulatory Framework
5. Porter’s Five Forces Analysis
5. U.S PrEP Market Disease Insights
1. Epidemiology of HIV/AIDS

5.2.   HIV Diagnoses

3. Incidence Rate of HIV/AIDS
4. Regulatory Scenario by Key Countries
5. Overview of Current Advances in R&D for HIV Drugs
6. U.S. PrEP (Pre-Exposure Prophylaxis) Market Size & Forecast by Value, 2017-2027
7. Competitive Landscape
1. List of Key Players and Their Offerings
2. Market Share Analysis (2020)
3. Competitive Benchmarking, By Operating Parameters
4. Key Strategies Employed by Market Leaders
8. Brand Analysis of PrEP
9. Impact of COVID-19 on U.S. PrEP Market

10. Company Profiles (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *

10.1. Gilead Sciences Inc.

10.2. Lupin

10.3. Strides Pharma Science Limited

10.4. Teva Pharmaceutical Industries Ltd.

10.5 List of Companies Under Clinical Development of PrEP Drugs

11. Key Strategic Recommendations

*Financial details of unlisted companies will be available as per data availability in final deliverable

**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable.

List of Figures

Figure 1: Advantages of PrEP

Figure 2:  Simplified Conceptual Diagram of Health States in The Markov Model

Figure 3:  U.S. PrEP Healthcare Industry Value Chain

Figure 4:  Process of a Drug Clinical Trial & Approval

Figure 5:  Scatterplot of HIV Prevalence by US County Population Stratified by US Census Region, 2018

Figure 6:  PrEP Coverage, by State, United States, 2018

Figure 7:  Estimated Raw Number of LGBT People (Ages 13+) Living in Each State

Figure 8:  Porters Five Forces Analysis

Figure 9 Number of New HIV Diagnoses by US County, 2018

Figure 10:  Diagnosed HIV Prevalence by US County, 2018

Figure 11:  Scatterplot of HIV Prevalence by US County Population Stratified by US Census Region, 2018

Figure 12:  HIV Diagnoses Overall andby Age inThe USA, 2009–18

Figure 13:  Annual Number of HIV Infections 2015-2019

Figure 14: Composition of the Global HIV Prevention R&D Investment Base, 2018-2019

Figure 15:  The Future of Antiretroviral Medications-Based Prevention and More (June 2021)

Figure 16:  Investment in Women Focused PrEP R&D, 2019

Figure 17:  U.S. PrEP (Pre-Exposure Prophylaxis) Market Size, By Value (USD Million), 2020-2027

Figure 18 Company Market Share Analysis, 2020

List of Tables

Table 1: New HIV Diagnoses in the US and Dependent Areas by Age at Diagnosis, 2019

Table 2:  New HIV Diagnoses Among Adults and Adolescents in the US and Dependent Areas by Race/Ethnicity, 2019

Table 3: New HIV Diagnoses Among Adults and Adolescents in the US and Dependent Areas by Transmission Category, 2019

Table 4: New HIV Diagnoses Among Adults and Adolescents by Top 10 States, 2019

Table 5: States with Laws That Broadly Allow Minors to Autonomously Consent to Any Health Care Services or Procedures

Table 6: Competitive Benchmarking, by Operating Parameters

Table 7: Brand Comparison Amidst Descovy V/S Truvada

Table 8: GiLead Sciences Inc. Overview

Table 9: GiLead Sciences Inc. Financial Analysis (USD Million)

Table 10:  Lupin Overview

Table 11:   Strides Pharma Science Limited Overview

Table 12: Teva Pharmaceutical Industries Ltd. Overview

Table 13: Teva Pharmaceutical Industries Ltd. Financial Analysis (USD Million)

Table 14:  List of Companies Under Clinical Development of PrEP Drugs